-+ 0.00%
-+ 0.00%
-+ 0.00%

Q32 Bio announced that it will announce the latest breakthrough results from part B of the Signal-AA clinical trial of Bempikibart to treat alopecia areata at the 2026 European Society of Dermatology and Venereology conference.

智通财经·09/21/2026 13:25:08
语音播报
Q32 Bio announced that it will announce the latest breakthrough results from part B of the Signal-AA clinical trial of Bempikibart to treat alopecia areata at the 2026 European Society of Dermatology and Venereology conference.